ERBB2 and gastric neoplasm: The ToGA trial1 demonstrated that the combination of trastuzumab with chemotherapy significantly improved outcomes in patients with HER2-positive/IHC 3+ gastric tumors, with a hazard ratio (HR) of 0.58, and an overall response rate (ORR) of 47%, compared to 35% with chemotherapy alone.